Zhang Y - Search Results

1

A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population.

Zhang Y, Fu X, Qi Y, Gao Q. Zhang Y, et al. Immunotherapy. 2019 Feb;11(2):91-99. doi: 10.2217/imt-2018-0030. Epub 2018 Dec 4. Immunotherapy. 2019. PMID: 30511592

2

Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.

Wang Z, Zhang Y, Liu Y, Wang L, Zhao L, Yang T, He C, Song Y, Gao Q. Wang Z, et al. Among authors: zhang y. J Immunother. 2014 Jan;37(1):43-50. doi: 10.1097/CJI.0000000000000005. J Immunother. 2014. PMID: 24316555

3

Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma.

Zhao L, Li W, Wang Z, Yang Y, Zhang Y, Shang Y, Ren X, Gao Q. Zhao L, et al. Among authors: zhang y. Immunotherapy. 2018 Mar 1;10(6):501-510. doi: 10.2217/imt-2017-0140. Immunotherapy. 2018. PMID: 29562855

4

Combination of PD-1 blockade and RetroNectin^®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study.

Zhao L, Han L, Zhang Y, Li T, Yang Y, Li W, Shang Y, Lin H, Gao Q. Zhao L, et al. Among authors: zhang y. Immunotherapy. 2018 Nov;10(15):1315-1323. doi: 10.2217/imt-2018-0125. Epub 2018 Oct 23. Immunotherapy. 2018. PMID: 30350739

5

Clinical value of neutrophil-to-lymphocyte ratio as a predictor of prognosis of RetroNectin^®-activated cytokine-induced killer cell therapy in advanced non-small-cell lung cancer.

Zhao L, Li T, Yang Y, Zhang Y, Li W, Han L, Shang Y, Lin H, Ren X, Gao Q. Zhao L, et al. Among authors: zhang y. Immunotherapy. 2019 Mar;11(4):273-282. doi: 10.2217/imt-2018-0147. Epub 2018 Dec 14. Immunotherapy. 2019. PMID: 30547699

6

Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy.

Qi Y, Liao D, Fu X, Gao Q, Zhang Y. Qi Y, et al. Among authors: zhang y. Int Immunopharmacol. 2019 Sep;74:105707. doi: 10.1016/j.intimp.2019.105707. Epub 2019 Jul 1. Int Immunopharmacol. 2019. PMID: 31272066

7

Cytokine-induced killer cell therapy-associated idiopathic thrombocytopenic purpura: rare but noteworthy.

Fu X, Zhang Y, Gao Q, Lin J, Zhang Q, Xu B, Song Y. Fu X, et al. Among authors: zhang q, zhang y. Immunotherapy. 2016 Sep;8(9):1003-9. doi: 10.2217/imt-2016-0065. Immunotherapy. 2016. PMID: 27485074

8

Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients.

Zhang Y, Zhu Y, Zhao E, He X, Zhao L, Wang Z, Fu X, Qi Y, Ma B, Song Y, Gao Q. Zhang Y, et al. Immunotherapy. 2017 Nov;9(14):1165-1174. doi: 10.2217/imt-2017-0061. Immunotherapy. 2017. PMID: 29067881

9

Platelet-to-lymphocyte ratio in peripheral blood: A novel independent prognostic factor in patients with melanoma.

Qi Y, Zhang Y, Fu X, Wang A, Yang Y, Shang Y, Gao Q. Qi Y, et al. Among authors: zhang y. Int Immunopharmacol. 2018 Mar;56:143-147. doi: 10.1016/j.intimp.2018.01.019. Epub 2018 Feb 3. Int Immunopharmacol. 2018. PMID: 29414644

10

Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer.

Fu X, Zhang Y, Yang J, Qi Y, Ming Y, Sun M, Shang Y, Yang Y, Zhu X, Gao Q. Fu X, et al. Among authors: zhang y. Onco Targets Ther. 2018 Sep 20;11:6091-6100. doi: 10.2147/OTT.S174138. eCollection 2018. Onco Targets Ther. 2018. PMID: 30275713 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256,819 results

Search Page

Filters